OBJECTIVE: Dysregulation of maternal circulating adipokines has been implicated in several "great obstetrical syndromes" including preeclampsia (PE), small-for-gestational age (SGA) neonate and fetal death (FD). It has been suggested that adipokines provide a molecular link between metabolic derangements and inflammatory response in complicated pregnancies. Retinol binding protein 4 (RBP4), a novel adipokine, plays a role in obesity-related disorders, as well as in the regulation of the immune response. The aim of this study was to determine whether there are changes in maternal plasma concentrations of RBP4 in patients with PE and in those with an SGA neonate or FD. STUDY DESIGN: This cross-sectional study included patients in the following groups: 1) normal pregnancy (n=134); 2) PE (n=104); 3) SGA neonate (n=28); and 4) FD (n=37). Maternal plasma RBP4 concentrations were determined by ELISA. Non-parametric statistics were used for analysis. RESULTS: 1) The median maternal plasma RBP4 concentration was higher among patients with PE than in those with a normal pregnancy (P=0.03); 2) The median maternal plasma RBP4 concentrations of patients with preterm PE (<37 weeks) was higher than that of those with term PE (P=0.017) and than that of those with a normal pregnancy (P=0.002); 3) The median maternal plasma RBP4 concentration did not differ significantly between patients with a normal pregnancy and those with an SGA neonate or with an FD; 4) Among normal pregnant women, the maternal plasma RBP4 concentrations did not correlate with pre-pregnancy body mass index, gestational age at blood sampling and neonatal birthweight. CONCLUSIONS: 1) Preeclampsia, but not pregnancy with an SGA neonate or an FD, is associated with a higher median maternal plasma concentration of RBP4 than normal pregnancy; 2) Preterm PE, and specifically early-onset PE, is associated with higher median RBP4 concentrations in maternal plasma compared to term PE. These findings suggest a role for RBP4 in the pathogenesis of preterm PE, but not in SGA and FD.
OBJECTIVE: Dysregulation of maternal circulating adipokines has been implicated in several "great obstetrical syndromes" including preeclampsia (PE), small-for-gestational age (SGA) neonate and fetal death (FD). It has been suggested that adipokines provide a molecular link between metabolic derangements and inflammatory response in complicated pregnancies. Retinol binding protein 4 (RBP4), a novel adipokine, plays a role in obesity-related disorders, as well as in the regulation of the immune response. The aim of this study was to determine whether there are changes in maternal plasma concentrations of RBP4 in patients with PE and in those with an SGA neonate or FD. STUDY DESIGN: This cross-sectional study included patients in the following groups: 1) normal pregnancy (n=134); 2) PE (n=104); 3) SGA neonate (n=28); and 4) FD (n=37). Maternal plasma RBP4 concentrations were determined by ELISA. Non-parametric statistics were used for analysis. RESULTS: 1) The median maternal plasma RBP4 concentration was higher among patients with PE than in those with a normal pregnancy (P=0.03); 2) The median maternal plasma RBP4 concentrations of patients with preterm PE (<37 weeks) was higher than that of those with term PE (P=0.017) and than that of those with a normal pregnancy (P=0.002); 3) The median maternal plasma RBP4 concentration did not differ significantly between patients with a normal pregnancy and those with an SGA neonate or with an FD; 4) Among normal pregnant women, the maternal plasma RBP4 concentrations did not correlate with pre-pregnancy body mass index, gestational age at blood sampling and neonatal birthweight. CONCLUSIONS: 1) Preeclampsia, but not pregnancy with an SGA neonate or an FD, is associated with a higher median maternal plasma concentration of RBP4 than normal pregnancy; 2) Preterm PE, and specifically early-onset PE, is associated with higher median RBP4 concentrations in maternal plasma compared to term PE. These findings suggest a role for RBP4 in the pathogenesis of preterm PE, but not in SGA and FD.
Authors: Joey P Granger; Barbara T Alexander; Maria T Llinas; William A Bennett; Raouf A Khalil Journal: Microcirculation Date: 2002-07 Impact factor: 2.628
Authors: T Chaiworapongsa; R Romero; J Yoshimatsu; J Espinoza; Y M Kim; K Park; K Kalache; S Edwin; E Bujold; R Gomez Journal: J Matern Fetal Neonatal Med Date: 2002-07
Authors: Shali Mazaki-Tovi; Edi Vaisbuch; Roberto Romero; Juan Pedro Kusanovic; Tinnakorn Chaiworapongsa; Sun Kwon Kim; Giovanna Ogge; Bo Hyun Yoon; Zhong Dong; Juan M Gonzalez; Maria Teresa Gervasi; Sonia S Hassan Journal: Am J Reprod Immunol Date: 2010-02-18 Impact factor: 3.886
Authors: Pooja Mittal; Roberto Romero; Adi L Tarca; Sorin Draghici; Chia-Ling Nhan-Chang; Tinnakorn Chaiworapongsa; John Hotra; Ricardo Gomez; Juan Pedro Kusanovic; Deug-Chan Lee; Chong Jai Kim; Sonia S Hassan Journal: Am J Obstet Gynecol Date: 2011-02 Impact factor: 8.661
Authors: Pooja Mittal; Roberto Romero; Adi L Tarca; Juan Gonzalez; Sorin Draghici; Yi Xu; Zhong Dong; Chia-Ling Nhan-Chang; Tinnakorn Chaiworapongsa; Stephen Lye; Juan Pedro Kusanovic; Leonard Lipovich; Shali Mazaki-Tovi; Sonia S Hassan; Sam Mesiano; Chong Jai Kim Journal: J Perinat Med Date: 2010-07-14 Impact factor: 1.901
Authors: Daniel B DiGiulio; Mariateresa Gervasi; Roberto Romero; Shali Mazaki-Tovi; Edi Vaisbuch; Juan Pedro Kusanovic; Kimberley S Seok; Ricardo Gómez; Pooja Mittal; Francesca Gotsch; Tinnakorn Chaiworapongsa; Enrique Oyarzún; Chong Jai Kim; David A Relman Journal: J Perinat Med Date: 2010-09 Impact factor: 1.901
Authors: Arrigo Fruscalzo; R Schmitz; W Klockenbusch; G Köhler; A P Londero; M Siwetz; B Huppertz Journal: Histochem Cell Biol Date: 2012-07-31 Impact factor: 4.304
Authors: Dejene F Abetew; Chunfang Qiu; Neway G Fida; Michal Dishi; Karin Hevner; Michelle A Williams; Daniel A Enquobahrie Journal: Diabetes Res Clin Pract Date: 2012-11-13 Impact factor: 5.602
Authors: Shali Mazaki-Tovi; Adi L Tarca; Edi Vaisbuch; Juan Pedro Kusanovic; Nandor Gabor Than; Tinnakorn Chaiworapongsa; Zhong Dong; Sonia S Hassan; Roberto Romero Journal: J Perinat Med Date: 2016-10-01 Impact factor: 1.901